Reduced dose and reduced exposure to non-vitamin K-antagonist oral anticoagulants: Some considerations on this relationship

被引：1
|
作者：
Rubboli, Andrea [1 ]
Verheugt, Freek W. A. [2 ]
机构：
[1] Osped Maggiore Bologna, Lab Intervent Cardiol, Div Cardiol, Largo Nigrisoli 2, I-40133 Bologna, Italy
[2] OLVG, Heartctr, Dept Cardiol, Oosterpk 9, NL-1091 AC Amsterdam, Netherlands
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2016年 / 223卷
关键词：
Non-vitamin K-antagonist oral anticoagulants; Oral anticoagulation; ATRIAL-FIBRILLATION; RENAL-FUNCTION; WARFARIN; RIVAROXABAN; DABIGATRAN; APIXABAN; EFFICACY; SAFETY;
D O I：
10.1016/j.ijcard.2016.08.207
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：519 / 520
页数：2
相关论文
共 50 条
  • [41] Intracerebral hemorrhage associated with warfarin versus non-vitamin K antagonist oral anticoagulants in Asian patients
    Woo, Ho Geol
    Chung, Inyoung
    Gwak, Dong Seok
    Kim, Baik Kyun
    Kang, Ji Hoon
    Kim, Beom Joon
    Bae, Hee-Joon
    Han, Moon-Ku
    JOURNAL OF CLINICAL NEUROSCIENCE, 2019, 61 : 160 - 165
  • [42] Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
    Fanaroff, Alexander C.
    Vora, Amit N.
    Lopes, Renato D.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 : A19 - A31
  • [43] Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
    Undas, Anetta
    Drabik, Leszek
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2020, 23 (01) : 10 - 18
  • [44] Real-world comparisons of reduced-dose non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation: a systematic review and meta-analysis
    Wang, Xiaoping
    Fang, Lili
    Liu, Bin
    Zheng, Yongliang
    Zeng, Junquan
    HEART FAILURE REVIEWS, 2020, 25 (06) : 973 - 983
  • [45] Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study
    Xing, Lucas Yixi
    Barcella, Carlo Alberto
    Sindet-Pedersen, Caroline
    Bonde, Anders Nissen
    Gislason, Gunnar Hilmar
    Olesen, Jonas Bjerring
    THROMBOSIS RESEARCH, 2019, 178 : 101 - 109
  • [46] Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation
    Park, Susin
    Je, Nam Kyung
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2021, 26 (06) : 656 - 664
  • [47] OVERVIEW OF NON-VITAMIN K ORAL ANTICOAGULANTS
    Cirstea, Iulia Madalina
    Mindrila, Bogdan
    Tieranu, Eugen
    Tieranu, Loredana Maria
    Istratoaie, Octavian
    Militaru, Constantin
    Donoiu, Ionut
    FARMACIA, 2020, 68 (02) : 206 - 212
  • [48] The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation
    Vinding, Naja Emborg
    Bonde, Anders Nissen
    Rorth, Rasmus
    Lamberts, Morten
    Olesen, Jonas Bjerring
    Gislason, Gunnar Hilmar
    Torp-Pedersen, Christian
    Kober, Lars
    Fosbol, Emit Loldrup
    EUROPACE, 2019, 21 (04): : 572 - 579
  • [49] Pros and Cons of Vitamin K Antagonists and Non-Vitamin K Antagonist Oral Anticoagulants
    Riva, Nicoletta
    Ageno, Walter
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2015, 41 (02) : 178 - 187
  • [50] Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
    Li, Wenhao
    Zhou, Yanxia
    Chen, Siqi
    Zeng, Dewang
    Zhang, Haidong
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
12345